Clinical trials have only shown modest effects of PPARα (fibrates) and PPARγ (thiazolidinediones and pioglitazone) agonists in reversing ART lipoatrophy [94,95], while other studies suggested these drugs may be useful in treating ART-associated diabetes and NAFLD [96]. Here, PPARA is linked to diabetes mellitus.